Idenix Pharmaceuticals (IDIX) - profile

Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company’s research and development focus is on the treatment of hepatitis C virus (HCV). In July 2011, it initiated a phase IIb clinical trial of IDX184 in combination with pegylated interferon and ribavirin (Peg-IFN/RBV), in treatment- HCV genotype 1-infected patients. Its drug candidate for its NS5A inhibitor program is IDX719. In December 2011, it filed an investigational new drug application (IND) for IDX719 and in January 2012, it initiated a phase I clinical study.

Address

60 Hampshire Street

CAMBRIDGE, MA 02139

United States

Key stats and ratios

	Q1 (Mar '13)	2012
Net profit margin	-3609.51%	-46.51%
Operating margin	-3641.20%	-50.79%
EBITD margin	-	-33.84%
Return on average assets	-51.68%	-16.53%
Return on average equity	-60.50%	-23.97%
Employees	107

Hepatitis C
As of December 31, 2011, the Company was developing nucleoside/nucleotide polymerase inhibitors and NS5A inhibitors to inhibit HCV replication, which include nucleoside/nucleotide polymerase inhibitors and NS5A inhibitors. During HCV replication, the viral polymerase, also called the NS5B polymerase, is an enzyme, which replicates the viral genetic information contained in the HCV viral genetic material, which is known as viral ribonucleic acid (RNA). NS5A is a multifunctional, nonstructural HCV protein, which is for the formation of viral replication complexes, the process of viral replication and virus assembly. IDX184 is a liver-targeted nucleotide prodrug, which enables the delivery of nucleoside monophosphate to the liver, leading to the formation of nucleoside triphosphate. Its drug candidate for its NS5A inhibitor program is IDX719. In December 2011, it filed an IND for IDX719 and in January 2012, it initiated a phase I clinical study in healthy volunteers. Its drug candidate for its non-nucleoside polymerase inhibitor program was IDX375, a palm-binding polymerase inhibitor.

HIV
The Company has developed a non-nucleoside reverse transcriptase inhibitor (NNRTI), drug candidate, IDX899, for the treatment of human immunodeficiency virus type-1 (HIV), and acquired immune deficiency syndrome (AIDS), for use in combination therapy. In February 2011, ViiV Healthcare Company (ViiV) informed it that the Food and Drug Agency (FDA) placed ‘761 on clinical hold.

Hepatitis B
In collaboration with Novartis, the Company developed telbivudine (Tyzeka/Sebivo) through commercialization for the treatment of patients with HBV. As of December 31, 2011, Novartis Pharma AG (Novartis) has been responsible for clinical trial costs and related expenditures associated with telbivudine.

Antiviral Research
The Company has developed set of skills in compound generation, target selection, screening and pharmacology, preclinical development and lead optimization. It is utilizing these skills and capabilities in its discovery and development of antiviral drug candidates.
The Company competes with Abbott Laboratories, Boehringer Ingelheim International GmbH, F. Hoffman-LaRoche & Co., Johnson & Johnson, Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis, Gilead Sciences, Inc., Vertex Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc., Enanta Pharmaceuticals, Inc. and Presidio Pharmaceuticals, Inc.

*** 16 June 2013: daily, weekly and monthly charts **